Robert Flello – 2014 Parliamentary Question to the Department of Health
The below Parliamentary question was asked by Robert Flello on 2014-06-12.
To ask the Secretary of State for Health, if he will take steps to prevent NHS England from implementing restrictions on the use of new drugs for advanced prostate cancer, enzalutamide and abiraterone.
Norman Lamb
The National Institute for Health and Care Excellence (NICE) published technology appraisal guidance in June 2012 which recommends abiraterone (Zytiga) in its licensed indication for the treatment of castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen, subject to a patient access scheme agreed between the Department and the drug’s manufacturer.
NICE is currently appraising (i) abiraterone for the treatment of metastatic hormone relapsed prostate cancer not previously treated with chemotherapy and (ii) enzalutamide for metastatic hormone-relapsed prostate cancer in adults whose disease has progressed during or after docetaxel-containing chemotherapy.
National Health Service commissioners are legally required to fund those treatments recommended by NICE in its technology appraisal guidance.
In the absence of NICE technology appraisal guidance it is for the relevant NHS commissioner to make funding decisions based on an assessment of the available evidence. The NHS Constitution states that patients have the right to expect local decisions on the funding of drugs and treatments ‘to be made rationally following a proper consideration of the evidence’.
We understand that abiraterone as a first-line treatment is available through the Cancer Drugs Fund to NHS patients in England who could benefit from it, and that enzalutamide is also available through the Cancer Drugs Fund to patients who meet specified clinical criteria.
